Brief: Halozyme Therapeutics Q3 Adjusted EPS USD 1.27 Vs. IBES Estimate USD 0.98
31/10/2024 20:01
Oct 31 (Reuters) - Halozyme Therapeutics Q3 operating expenses USD 126.887 million. * Q3 net income USD 137.011 million * Q3 pretax profit USD 165.147 million * Q3 operating income USD 163.197 million * Q3 EPS USD 1.05
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets